Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

82.42USD
10:34am EDT
Change (% chg)

$0.47 (+0.57%)
Prev Close
$81.95
Open
$81.83
Day's High
$83.12
Day's Low
$81.49
Volume
77,121
Avg. Vol
1,117,230
52-wk High
$111.36
52-wk Low
$17.52

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $14,033.35
Shares Outstanding(Mil.): 171.24
Dividend: --
Yield (%): --

Financials

  NKTR.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -0.82 -- --
ROI: -29.70 -7.38 12.74
ROE: -249.67 -10.11 14.64

BRIEF-Nektar Therapeutics Reports Q1 Loss Per Share $0.60

* Q1 EARNINGS PER SHARE VIEW $-0.54 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Nektar Therapeutics Says CEO Howard W. Robin's 2017 Total Compensation Was $18.1 Million

* NEKTAR THERAPEUTICS SAYS CEO HOWARD W. ROBIN'S 2017 TOTAL COMPENSATION WAS $18.1 MILLION – SEC FILING

Apr 30 2018

BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors

* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS

Apr 24 2018

BRIEF-Nektar Therapeutics Q4 Loss Per Share $0.21

* Q4 REVENUE $95.5 MILLION VERSUS $37.5 MILLION Source text for Eikon: Further company coverage:

Mar 01 2018

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Feb 14 2018

UPDATE 1-Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Feb 14 2018

Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Feb 14 2018

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement

* NEKTAR THERAPEUTICS - ‍ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007​ Source text: (http://bit.ly/2BsgSdG) Further company coverage:

Dec 15 2017

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement

* NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018

Dec 12 2017

BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs

Nov 24 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,600 -76.00
Eisai Co., Ltd (4523.T) ¥8,013 -55.00
NOF CORPORATION (4403.T) ¥3,455 +35.00
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs1,954.35 -55.25
Novo Nordisk A/S (NOVOb.CO) kr.306.15 -2.15
Pfizer Inc. (PFE.N) $35.92 +0.20
Novartis AG (NOVN.S) CHF76.42 -0.26
Roche Holding Ltd. (ROG.S) CHF219.70 -4.20
Roche Holding Ltd. (RO.S) CHF224.00 -4.80
GlaxoSmithKline plc (GSK.L) 1,509.00 -0.20

Earnings vs. Estimates